Karanis Meryem, Koksal Hande, Ates Emet, Dogru Osman
Faculty of Medicine, Saglik Bilimleri University, Konya Education and Research Hospital, Turkey.
Pol J Pathol. 2019;70(4):259-263. doi: 10.5114/pjp.2019.93127.
The aim of this study was to evaluate the clinical importance of fibulin-5, which has been shown to display tumour-promoting and tumour-protective functions in breast lesions. Sixty-two breast cancer patients, 19 patients with fibroadenoma, and 15 healthy breast tissues were enrolled. Forty-seven patients had invasive ductal carcinoma (IDC) (12 of them also had in situ carcinoma DCIS), and 15 had invasive lobular carcinoma (ILC). A scoring system from 0 to 4 was used to evaluate the fibulin-5 staining according to the percentage of stained cells. The median values of fibulin-5 staining scores of the breast cancer, fibroadenoma, and healthy breast tissues were 2 (range: 0-4), 3 (range: 3-4), and 4 (range: 1-4), respectively, and the difference is statistically significant (p = 0.0001). There was no significant difference between the fibulin-5 scores of IDC, ILC, and DCIS. Fifteen patients with triple-negative breast cancer (TNBC) had the lowest fibulin-5 score (p < 0.0001). The median fibulin-5 scores of the patients according to Ki-67 index ≥ 14% and < 14% were 2 (range: 1-5) and 4 (range: 1-5), respectively, and the difference is statistically significant (p = 0.001). These data can be explained by the inhibitory effect of fibulin-5 on epithelial cell proliferation, which is closely related to differentiation and prognosis.
本研究的目的是评估纤连蛋白-5的临床重要性，该蛋白在乳腺病变中已显示出促进肿瘤和保护肿瘤的功能。纳入了62例乳腺癌患者、19例纤维腺瘤患者和15例健康乳腺组织。47例患者患有浸润性导管癌（IDC）（其中12例还患有原位癌DCIS），15例患有浸润性小叶癌（ILC）。根据染色细胞的百分比，使用0至4的评分系统评估纤连蛋白-5染色。乳腺癌、纤维腺瘤和健康乳腺组织的纤连蛋白-5染色评分中位数分别为2（范围：0-4）、3（范围：3-4）和4（范围：1-4），差异具有统计学意义（p = 0.0001）。IDC、ILC和DCIS的纤连蛋白-5评分之间无显著差异。15例三阴性乳腺癌（TNBC）患者的纤连蛋白-5评分最低（p < 0.0001）。根据Ki-67指数≥14%和<14%，患者的纤连蛋白-5评分中位数分别为2（范围：1-5）和4（范围：1-5），差异具有统计学意义（p = 0.001）。这些数据可以通过纤连蛋白-5对上皮细胞增殖的抑制作用来解释，上皮细胞增殖与分化和预后密切相关。
